WPD is announcing recruitment for the position of Project Managers to the Project Management Office at WPD Pharmaceuticals Sp. z o.o.

In relation to research projects carried out under the Smart Growth Operational Programme 2014-2020,Priority I: Support for Research and Development work by Small and Medium Enterprises, Measure: Research and Development Projects by Enterprises, Sub-Measure 1.1.1. Industrial Research and Development work by Enterprises,– we are announcing recruitment for the position of Project Managers to the Project Management Office at WPD Pharmaceuticals Sp. z o.o.


On March 13-15, 2019 we had great pleasure to attend the 11th International Conference on Contemporary Oncology, that took place in Poznań. During this event we had the opportunity to present to the wide range of specialist the assumption of preclinical research for the WPD101 molecule planned for implementation under the project: “Development of a new medicine used in the therapy of glioblastoma multiforme”, co-financed by the European Union from the European Regional Development Fund under the Smart Growth Operational Program 2014-2020, Priority I: Support for conducting R&D works by Medium and Small companies and Microenterprises, Sub-measure 1.1.1. Industrial research projects and Experimental development work projects carried out by companies.

On March 15, 2019 we had an honor and pleasure to present our activity during the XIII. meeting from the series of "On inventions in a neighborhood" organized by the Wroclaw Technology Park. The idea of this series of meeting is to exchange experiences and information as well as to seek opportunities for mutual cooperation.

The agreement provides WPD with exclusive rights, subject to current license agreements, to develop and market a range of Moleculin’s technologies in certain European countries (which does not include the UK, France, Italy and Spain) in exchange for contributing a minimum of $4 million in development expenditures agreed upon by Moleculin during the term of the agreement plus an ongoing royalty on future revenues. The agreement is specifically geared to provide Moleculin with the benefit of European Union (EU) grant funding, which is available to companies like WPD that are formed and present in EU countries. More.


On the 31th of January 2019 National Center for Research and Development announed a list of projects recommended for co-financing by the European Union, under the Smart Growth Operational Program 2014-2020, Sectoral Programme InnoNeuroPharm, Priority Axis I: Support R&D carried out by enterprises,Measure 1.2 Sectorial programms R&D.

On 23-24 May we participated in BioForum 2018 - the biggest partnering conference in Central Europe that provides the world’s most innovative leaders across the life science sector to network and do business with one another on pre-scheduled B2B meetings.

On June 21-23, 2018 we had a pleasure and honor to participate as one of the sponsors in the "Brain Tumors Meeting 2018 - From Biology to Therapy", which took place in Neurobiology Center, Nencki Institute of Experimental Biology.

On November 14-16, 2018, the XI Multidisciplinary Conference on Drug Science was held in Warsaw. This year the main theme was "Science for industry, industry for science". The conference was organized by the Pharmaceutical Institute in Warsaw. WPD Pharmaceuticals presented a preclinical development plan for the WPD101 for use in targeted therapy of glioblastoma.